Pediatr. praxi. 2012;13(3):188-192

Depression and maternal antidepressant therapy from the perspective of neonatologist

MUDr.Alice Mocková, MUDr.Veronika Nováková, MUDr.Zuzana Lucková, doc.MUDr.Jiří Dort, Ph.D.
Neonatologické oddělení FN Plzeň

Depression and the use of antidepressants during pregnancy may have a negative influence on fetal development as well as adaptation

during the neonatal period. The aim of our study was to elicit the effect of antidepressant use during pregnancy on postnatal adaptation

and the incidence of congenital abnormalities. In a cohort of forty two antidepressant using mothers, a higher incidence of prematurity

and hyperbilirubinemia was found. Furthermore children had smaller head circumferences (p < 0.05), and discontinuation syndrome was

diagnosed in 26 % (2 children had seizures), only 52 % were fully breast-fed. 12 % of children had a non-serious congenital abnormality. Further

studies are needed to ascertain the long-term developmental and cognitive effects of in utero exposure to antidepressant agents.

Keywords: pregnancy, depression, neonate, discontinual syndrom

Published: June 18, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mocková A, Nováková V, Lucková Z, Dort J. Depression and maternal antidepressant therapy from the perspective of neonatologist. Pediatr. praxi. 2012;13(3):188-192.
Download citation

References

  1. Strunzová V. Terapie deprese, úzkostných poruch a nespavosti v graviditě a laktaci. Psychiatria pre prax 2005; 1: 27-32.
  2. Cantor Sackett J, Weller RA, Weller EB. Selective serotonin reuptake inhibitor use during pregnancy and possible neonatal complications. Curr Psychiatry Rep. 2009; 11(3): 253-257. Go to original source... Go to PubMed...
  3. Belik J. Fetal and Neonatal Effects of Maternal Drug Treatment for Depression Seminars in Perinatology, 2008; 5: 350-354.
  4. Lubchenco LO, Hansman C, Boyd E. Intrauterine growth in length and head circumference as estimated from live births at gestational ages from 26 to 42 weeks. Pediatrics 1966; 37: 403-408. Go to original source... Go to PubMed...
  5. Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposure to antidepressant medication. American journal of Obstetrics and Gynaecology 2003; 188(3): 812-815. Go to original source... Go to PubMed...
  6. Wogelius P, Norgaard M, Muff Munk E, et al. Maternal use of selective serotonin reuptake inhibitors and risk of adverse pregnancy outcomes. Pharmacoepidemiology and Drug Safety 2005; 14: S143.
  7. Kulin NA, Pastuszak A, Sage S, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors - A prospective controlled multicenter study. JAMA 1998; 279: 609-610. Go to original source... Go to PubMed...
  8. Seifertová D, Mohr M, Strunzová V. Léčba psychofarmaky v těhotenství a laktaci. Psychiatr. prax; 2007; 3: 118-124.
  9. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356(26): 2675-2683. Go to original source... Go to PubMed...
  10. Gentile S, Bellantuono C. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine. J Clin Psychiatry 2009; 70(3): 414-422. Go to original source... Go to PubMed...
  11. Alwan S, Reefhuis J, Rasmussen S, et al. Maternal use of selective serotonin re-uptake inhibitors and risk for birth defects [abstract]. Birth Defects Research (Part A): Clinical and Molecular Teratology 2005; 731: 291.
  12. Unfred CL, Chambers CD, Felix R, et al. Outcomes among pregnant women taking paroxetine (Paxil) [abstract], Organization of Teratology Information Services, 14th Annual Meeting Program, 2001.
  13. Honein MA, Paulozzi LJ, Cragan JD, et al. Evaluation of selected characteristics of pregnancy drug registry. Teratology 1999; 60: 356-364. Go to original source... Go to PubMed...
  14. Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006; 21: 221-222. Go to original source... Go to PubMed...
  15. Levkovitz, Y, Gil-Ad I, Zeldich E, Dayag M. Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines. Evidence for p-c-Jun, cytochrome c, and caspase-3 involvement. J Mol Neurosci. 2005; 27(1): 29-42. Go to original source... Go to PubMed...
  16. Xu Y, Sari Y, Zhou FC. Selective serotonin reuptake inhibitor disrupts organization of thalamocortical somatosensory barrels during. Developmental Brain Research, 2004, 21; 150(2): 151-161. Go to original source... Go to PubMed...
  17. Chambers CD, Johson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010-1015. Go to original source... Go to PubMed...
  18. Klinger G, Merlob P. Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. Isr J Psychiatry Relat Sci 2008; 45(2): 107-113. Go to PubMed...
  19. Lattimore KA, SM, Kaciroti N, et al. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol 2005; 25: 595-604. Go to original source... Go to PubMed...
  20. Ferreira, E, Carceller, AM, Agogue, C, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 2007; 119: 52. Go to original source... Go to PubMed...
  21. Eyal, R, Yaeger, D. Poor neonatal adaptation after in utero exposure to duloxetine. Am J Psychiatry 2008; 165: 651. Go to original source... Go to PubMed...
  22. Schmidt K, Olesen OV, Jensen PN. Citalopram and breastfeeding: serum concentrations and side effects in the infant. Biol Psychiatry 2000; 47: 164-165. Go to original source... Go to PubMed...
  23. Hallberg P, Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. Journal of Clinical Psychopharmacology 2005; 25(1): 59-73. Go to original source... Go to PubMed...
  24. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336: 258-262. Go to original source... Go to PubMed...
  25. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159: 1889-1895. Go to original source... Go to PubMed...
  26. Misri S, Reebye P, Kendrick K, et al. Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry. 2006; 163(6): 1026-1032. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.